{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:12:00Z","timestamp":1770977520172,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":7072,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1097\/01.mp.0000086487.78558.7d","type":"journal-article","created":{"date-parts":[[2003,9,17]],"date-time":"2003-09-17T21:53:13Z","timestamp":1063835593000},"page":"937-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2\/neu Status in Primary Breast Carcinoma using Tissue Microarray"],"prefix":"10.1016","volume":"16","author":[{"given":"Kyeongmee","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungjig","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/01.MP.0000086487.78558.7D_bib1","first-page":"1729","article-title":"p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity","volume":"6","author":"Stern","year":"1986","journal-title":"Mol Cell Biol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1990.8.1.103","article-title":"Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer","volume":"8","author":"Paik","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.1992.10.7.1044","article-title":"Prognostic significance of HER-2 oncoprotein expression in breast cancer. A 30-yr follow-up","volume":"10","author":"Toikkanen","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/90.18.1361","article-title":"erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer","volume":"90","author":"Paik","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer","volume":"330","author":"Muss","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib7","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1073\/pnas.89.12.5321","article-title":"ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization","volume":"89","author":"Kallioniemi","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib8","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","article-title":"HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas","volume":"15","author":"Press","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib9","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.2001.19.10.2714","article-title":"Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positive do not get the message","volume":"19","author":"Tubbs","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","article-title":"Chromogenic in situ hybridization. A practical alternative for fluorescence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples","volume":"157","author":"Tanner","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ng1296-457","article-title":"Use of a cDNA microarray to analyze gene expression patterns in human cancer","volume":"14","author":"DeRisi","year":"1996","journal-title":"Nat Genet"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/hmg\/10.7.657","article-title":"Tissue microarray technology for high-throughput molecular profiling of cancer","volume":"10","author":"Kallioniemi","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer\u2014experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib15","first-page":"97","article-title":"Nuclear structure in cancer tissue","volume":"105","author":"Black","year":"1957","journal-title":"Surg Gynecol"},{"issue":"Suppl","key":"10.1097\/01.MP.0000086487.78558.7D_bib16","first-page":"43","article-title":"Tissue microarrays (\u201ctissue chips\u201d) for high-throughput cancer genetics: Linking molecular changes to clinical endpoints","volume":"65","author":"Bucher","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH721>3.0.CO;2-0","article-title":"Multiple tissue core arrays in histopathology research: a validation study","volume":"192","author":"Gillett","year":"2000","journal-title":"J Pathol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib18","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/labinvest.3780204","article-title":"Validation of tissue microarray technology in breast carcinoma","volume":"80","author":"Camp","year":"2000","journal-title":"Lab Invest"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib19","first-page":"63","article-title":"Detection and quantitation of HER-2\/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization","volume":"13","author":"Pauletti","year":"1996","journal-title":"Oncogene"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib20","first-page":"2771","article-title":"Sensitivity of HER-2\/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1999.17.1.434","article-title":"Increased Her-2 with US Food and Drug Administration approved antibody","volume":"17","author":"Roche","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.MP.0000086487.78558.7D_bib22","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.1999.17.7.1983","article-title":"Specificity of HercepTest in determining Her-2\/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system","volume":"17","author":"Jacobs","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222047354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222047354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T04:28:45Z","timestamp":1676262525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222047354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["S0893395222047354"],"URL":"https:\/\/doi.org\/10.1097\/01.mp.0000086487.78558.7d","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2003,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2\/neu Status in Primary Breast Carcinoma using Tissue Microarray","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/01.MP.0000086487.78558.7D","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}